Abstract
Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.
Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID
Current Drug Targets
Title: Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Volume: 12 Issue: 13
Author(s): Ronan J. Kelly, Ariel Lopez-Chavez and Eva Szabo
Affiliation:
Keywords: cancer, chemoprevention, clinical trials, carcinogenesis, efficacy, EGFR, safety, oncologic, phase III trials, NSAID
Abstract: Preclinical models and data from clinical trials suggest that cancer is a preventable disease. However, demonstration of a preventive effect requires large phase III clinical trials of long duration and involves many thousands of participants. The decision to proceed with phase III studies therefore must be informed by robust efficacy and safety data. This requires a systematic review of all available preclinical, epidemiological, and clinical data, along with a mechanistic understanding of the biology of the disease under study. In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions.
Export Options
About this article
Cite this article as:
J. Kelly Ronan, Lopez-Chavez Ariel and Szabo Eva, Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials, Current Drug Targets 2011; 12 (13) . https://dx.doi.org/10.2174/138945011798184173
DOI https://dx.doi.org/10.2174/138945011798184173 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
From Models to Molecules: Integrative Strategies in Herbal Product-based Drug Discovery
The toxic effects of synthetic drugs underscore the complex equilibrium between their therapeutic efficacy and the potential hazards they pose to biological systems. Natural products, with their diverse bioactive compounds and natural synergism, can help counteract synthetic drug toxicities by offering a complementary multi-targeted approach to mitigate organ damage and ...read more
New Drug Therapy for Eye Diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine The Immunohistochemical Assessment of HPV Related Adenocarcinoma: Pathologic and Clinical Prognostic Significance
Current Pharmaceutical Design The Fractal Viewpoint of Tumors and Nanoparticles
Current Medicinal Chemistry Nonviral Approach for Targeted Nucleic Acid Delivery
Current Medicinal Chemistry Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases – Structure, Mechanisms and Biomedical Effects#
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Synthesis, DPPH Radical Scavenging, Cytotoxic Activity, and Apoptosis Induction Efficacy of Novel Thiazoles and Bis-thiazoles
Current Organic Synthesis The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Biotechnology Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Molecular Insight and Binding Pattern Analysis of Shikonin as a Potential VEGFR-2 Inhibitor
Current Enzyme Inhibition lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Albumin-Based Nanodevices as Drug Carriers
Current Pharmaceutical Design Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy
Current Medicinal Chemistry SETD1A-mediated Methylation of H3K4me3 Inhibits Ferroptosis in Non-small Cell Lung Cancer by Regulating the WTAPP1/WTAP Axis
Current Medicinal Chemistry Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology